Differences in clinical features and prognosis between orbit adenoid cystic carcinoma and adenocarcinoma: a study from the SEER 18 database

Abstract

Purpose: To analyze the differences in clinical features, treatment methods, prognosis, and etiological factors between lacrimal gland, adenoid cystic carcinoma (LGACC), and orbit adenocarcinoma. Material and Methods: All cases of LGACC and orbit adenocarcinoma between 1975 and 2016 were obtained from the US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Results: The 3-, 5-, and 10-year overall survival (OS) rates for 118 LGACC cases were 82.2%, 70.2%, and 51.7%, respectively. The 3-, 5-, and 10-year OS rates for 29 orbit adenocarcinoma cases were 76.3%, 51.2%, and 51.2%, respectively. There was no statistically significant difference in the overall survival rate between LGACC and adenocarcinoma (P=0.566). Univariate analysis showed that the proportion of deaths was higher with increased age and year of diagnosis in LGACC (P=0.010 and P=0.000), while the death rate was higher for poorly differentiated adenocarcinoma (P=0.020). The survival rate for LGACC was lower in patients ⩾60 years of age than in those <60 years of age (P=0.035). There was no significant difference in survival rate between adenocarcinoma patients ⩾60 years and <60 years old (P=0.102). There was no significant correlation between the degree of tumor differentiation and the survival rate for LGACC or adenocarcinoma (P=0.401 or P=0.098, respectively). Conclusion: There is no significant difference in prognosis between LGACC and adenocarcinoma. The degree of tumor differentiation is not associated with prognosis for either LGACC or adenocarcinoma.

Oncogenic Proteomics Approaches for Translational Research and HIV-Associated Malignancy Mechanisms

“…In addition, they identified treatment guidance through four different Tumor Immune Microenvironment Types (TIMTs) that required further validation [ 62 ]. Lastly, relating to breast cancer, Adenoid Cystic Carcinoma (ACC), a rare indolent malignancy, has overlapping features with TNBC that can lead to unnecessary treatment via surgery or chemotherapy [ 63 , 64 ]. To provide a method to differ both neoplasms, a recent study compared protein expression in ACC and TNBC via mass spectrometry-based proteomics.…”

Comparative proteomic and clinicopathological analysis of breast adenoid cystic carcinoma and basal-like triple-negative breast cancer

“…Adenoid cystic carcinoma (ACC) is a malignant tumor that mostly occurs in the salivary glands, which can also affect other anatomical sites, such as the orbit, tracheobronchial tree, prostate, esophagus, and breast (1)(2)(3)(4)(5). Primary ACC of the breast is a rare form of invasive carcinoma comprising <0.1% of breast carcinomas (6).…”